Hexane

Hexane

SCHEMBL3615974

CCCCCC.CCN(CC)CC.CCOCC.CO

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PLA2G1B P04054 1/20 0.35
PLA2G2A P14555 1/20 0.35
TSHR P16473 3/20 0.35
THRB P10828 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
HTT P42858 1/20 0.34
MAPT P10636 1/20 0.34
ALDH1A1 P00352 3/20 0.33
LMNA P02545 2/20 0.33
HSD17B10 Q99714 1/20 0.33
CES2 O00748 1/20 0.32
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA9 Q16790 1/20 0.32
KDM5A P29375 1/20 0.32
KDM4C Q9H3R0 1/20 0.32
DNM1 Q05193 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hexane SCHEMBL2037219 0.95 TSHR (0.39) PLA2G1BPLA2G2ATSHRTHRBSMN1; SMN2
Ether SCHEMBL7862995 0.89 ALDH1A1 (0.38) TSHRMEN1KMT2AALDH1A1HSD17B10
Hexane SCHEMBL4267140 0.86 TSHR (0.47) TSHRTHRBSMN1; SMN2MEN1KMT2A
Hexane SCHEMBL27706711 0.86 TSHR (0.47) PLA2G1BPLA2G2ATSHRTHRBSMN1; SMN2
Hexane SCHEMBL5415595 0.83 TSHR (0.44) TSHRTHRBSMN1; SMN2MEN1KMT2A
Ether SCHEMBL324618 0.83 ALDH1A1 (0.35) MEN1KMT2AALDH1A1HSD17B10
Hexane SCHEMBL22319987 0.80 SMN1; SMN2 (0.47) PLA2G1BPLA2G2ATSHRTHRBSMN1; SMN2
Ether SCHEMBL7679488 0.80 ALDH1A1 (0.43) TSHRMEN1KMT2AALDH1A1HSD17B10
Pentane SCHEMBL27609734 0.80 TSHR (0.50) TSHRTHRBSMN1; SMN2MEN1KMT2A
Hexane SCHEMBL9422173 0.80 TSHR (0.54) PLA2G1BPLA2G2ATSHRTHRBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314110-B2 Compounds for treating mental disorders, and preparation and uses thereof LI YOUXIN (CN) 2012-11-20 US disclosed
US-20100113482-A1 Novel Compounds for Treating Mental Disorders, and Preparation and Uses Thereof LI YOUXIN 2010-05-06 US disclosed
EP-0639083-A1 COMPLEXING AGENTS AND TARGETING IMMUNOREAGENTS NYCOMED IMAGING AS (NO) 1995-02-22 EP disclosed
WO-1993021957-A1 COMPLEXING AGENTS AND TARGETING IMMUNOREAGENTS STERLING WINTHROP INC. (US) 1993-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113482-A1 Novel Compounds for Treating Mental Disorders, and Preparation and Uses Thereof SLC18A2, SLC6A3, SLC6A2 PLA2G1B 2410/4885PLA2G2A 2511/4885TSHR 799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.